Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Short term Debt (2018 - 2025)

Historic Short term Debt for Rockwell Medical (RMTI) over the last 10 years, with Q3 2025 value amounting to $1.8 million.

  • Rockwell Medical's Short term Debt fell 2084.43% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 2084.43%. This contributed to the annual value of $2.4 million for FY2024, which is 516.0% down from last year.
  • Rockwell Medical's Short term Debt amounted to $1.8 million in Q3 2025, which was down 2084.43% from $2.5 million recorded in Q2 2025.
  • Rockwell Medical's 5-year Short term Debt high stood at $21.1 million for Q2 2021, and its period low was $171000.0 during Q1 2021.
  • Moreover, its 5-year median value for Short term Debt was $2.5 million (2023), whereas its average is $4.6 million.
  • In the last 5 years, Rockwell Medical's Short term Debt surged by 1104609.7% in 2021 and then plummeted by 7790.27% in 2022.
  • Over the past 5 years, Rockwell Medical's Short term Debt (Quarter) stood at $7.4 million in 2021, then plummeted by 77.9% to $1.6 million in 2022, then soared by 53.28% to $2.5 million in 2023, then fell by 5.16% to $2.4 million in 2024, then fell by 24.08% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.5 million for Q2 2025, and $2.4 million during Q1 2025.